CareDx, Inc. (CDNA) FinancialsCDNACareDx, Inc.

CareDx, Inc. (CDNA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Testing Service revenue, accounting for 75.7% of total sales, equivalent to $99.93M. Other significant revenue streams include Digital and other revenue and Product revenue. Understanding this composition is critical for investors evaluating how CDNA navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, CareDx, Inc. maintains a gross margin of 73.50%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 85.81%, while the net margin is 83.85%. These profitability ratios, combined with a Return on Equity (ROE) of 29.49%, provide a clear picture of how effectively CDNA converts its operational activities into shareholder value.

In the context of the broader market, CDNA competes directly with industry leaders such as PLSE and VCYT. With a market capitalization of $3.47B, it holds a significant position in the sector. When comparing efficiency, CDNA's gross margin of 73.50% stands against PLSE's 37.10% and VCYT's 71.93%. Such benchmarking helps identify whether CareDx, Inc. is trading at a premium or discount relative to its financial performance.

CareDx has demonstrated significant revenue growth, with Q2 2026 revenue reaching $131.95 million, up from $108.39 million in Q4 2025. The net income for Q2 2026 was $110.64 million, showcasing a strong recovery after previous losses.